A Risk Based Approach to Improving Chronic Kidney Disease Management

Aim 1: To assess whether quality of care for stage 3 chronic kidney disease can be substantially improved over 18 months by:

• Point of care electronic alerts to primary care physicians recommending risk-appropriate care, and
• Quarterly mailings to patients providing self management support materials, including tailored recommendations based on personalized data from an electronic disease registry

Aim 2: To assess the relationship between utilization of the intervention components and primary care physician attitudes towards both chronic kidney disease management and electronic reminder systems.

Study Overview

• Status: Completed
• Conditions: Chronic Kidney Disease
• Intervention / Treatment: Other: Electronic Decision Support

Detailed Description

Specific Aim 1 We will develop software to calculate the estimated glomerular filtration rates for all patients presenting to primary care physicians randomized to the intervention arm, and identify patients with an estimated glomerular filtration rates in the range of 30 to 59. We will create three electronic alerts that intervention clinicians will receive upon accessing the patient chart based on whether the patient is high risk or low risk. These alerts will focus on recommending overdue laboratory tests (urine protein, blood cholesterol, etc), as well as recommending guideline appropriate medications (ACE inhibitors), and nephrology referral when appropriate.

We will provide self management support materials to patients of primary care physicians randomized to the intervention arm. We will rely on primary care physicians to enroll patients by first recommending referral via the electronic alerts. On a monthly basis, we will identify patient visits during which an alert fired and no referral was placed. We will distribute a list of these patients to each physician via inter-office mail at least every other month. The mailing will ask physicians to return the list indicating which patients should be enrolled in the program, and our project manager will place the referrals. For non-responding physicians, we will follow up with a reminder email. The patient mailings will include recent clinical results and guideline-recommended targets, encouraging patients to become more proactive in the management of their kidney disease. Once a patient is enrolled in the program, they will receive similar mailings with updated personalized data and recommendations every 3 months.

Electronic referrals placed by primary care physicians for management of chronic kidney disease will first be routed to the renal nurse, who will then initiate contact with the patient. A total of two telephone calls followed by a letter will be made to contact the patient. The nephrology visits will occur per standard clinical operations, including evaluation by an attending nephrologist, as well as educational sessions with the renal nurse and nutritionist. We will create new template notes within the electronic record for use by the nephrologists to communicate clinical care recommendations back to the primary care physicians.

Prior to starting the intervention, the study team will travel to each of the 14 health centers to conduct orientation sessions with the primary care physicians. These sessions will provide general information regarding the goals and scope of the upcoming intervention, including demonstrations of the electronic alerts and the self management support outreach program. A similar overview will also be provided to the HVMA Division of Nephrology.

We will randomize approximately 170 physicians into the intervention and control groups. Physicians in the intervention group will receive patient-specific alerts at the time of office visits for patients with Stage 3 kidney disease. Physicians in the control group will not receive active alerts.

Data will all be obtained electronically from automated extracts from the electronic health record. Our study endpoints will be measured at 18 months and are specified according to risk status. The primary endpoints among high risk patients will be 1) the presence of an office visit in nephrology within the prior 12 months, and 2) the use of ACE inhibitors or ARBs for those with hypertension or microalbuminuria. The primary endpoints among low risk patients will include 1) a urine microalbumin result within the prior 12 months, and 2) the use of ACE inhibitors or ARBs for those with hypertension or microalbuminuria. Hypertension will be assessed based on the presence of a most recent blood pressure greater than 130/80 mmHg or a current diagnosis of hypertension on the electronic problem list. A secondary endpoint for both patient groups will be achieving a blood pressure less than 130/80 mmHg. We will also assess primary care physician awareness of chronic kidney disease defined as use of appropriate problem list and encounter diagnosis codes; and rates of annual serum LDL cholesterol, hemoglobin, phosphorous, 25-OH-vitamin D, calcium, and parathyroid hormone testing; as well as rates of LDL cholesterol control (<100 mg/ dL) and anemia management (hemoglobin > 11 g/dL).

We will conduct an assessment of the self management support materials by surveying patients directly to assess 1) their ratings of the delivery of self-management support by our physician practice, 2) awareness of chronic kidney disease and treatment goals, and 3) the utility of the information contained in the patient mailings. These surveys will be conducted at two time points: baseline (first quarterly mailing) and completion of the study (final quarterly mailing). We will conduct the survey at two time points to facilitate an analysis of trends in patient experiences of care.

To assess the impact of the intervention on each of our primary outcomes we will fit hierarchical logistic regression models with random effects for patients within physicians and physicians within centers. We will fit a set of similar models among three subgroups defined by number of patient visits with their primary care physician during the 18 month period (0 visits, 1-2 visits, ≥ 3 visits). We will fit two secondary models that include a third independent variable for race or sex. The effect of the intervention on reducing race or sex-based disparities will be assessed by examining race*group and sex*group interaction terms.

Specific Aim 2 We will use the physician survey to collect data on primary care physician support for electronic reminders and patient self management, and preparedness to manage kidney disease. Physician responses will be collected using 5 point and 4 point Likert scales, and we will examine the distribution of responses for each survey item to create three dichotomous predictor variables of 1) high support for electronic reminders, 2) high support for patient self management, and 3) high preparedness for managing kidney disease. The primary outcomes will be the proportion of electronic alerts accompanied by ordering of 1) the recommended treatment, or 2) referral for patient self management support. We will construct three separate linear regression models for each dichotomous predictor variable defined above, with the proportion of times that the appropriate decision support feature is used as a continuous outcome variable. The dichotomous physician survey outcome measures will be used as the primary independent variables. We will further assess the statistical significance of an interaction term between physician randomization status and each of the three dichotomous survey outcomes in our primary models from Specific Aim 2 to test whether electronic alerts are more or less effective depending on physician reported attitudes.

• Study Type: Interventional
• Enrollment (Actual): 10000
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • Massachusetts
    • Newton, Massachusetts, United States, 02466
      • Harvard Vanguard Medical Associates

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Stage 3 chronic kidney disease based on at least 2 eGFR 30-60 (separated by 90 days) within the prior 5 years
• Must be at least 18 years of age
• Must have a primary care visit at one of 15 of the HVMA health centers within the last 18 months

Exclusion Criteria:

• Age > 85 years

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Health Services Research
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Physician Intervention; Physicians randomized to the intervention will receive: Electronic alerts during office visits for patients with chronic kidney disease; Opportunity to enroll their patients with chronic kidney disease in a self management support outreach program	Other: Electronic Decision Support; Physicians randomized to the intervention will receive: Electronic alerts during office visits for patients with chronic kidney disease; Opportunity to enroll their patients with chronic kidney disease in a self management support outreach program
No Intervention: Physician Control; Physicians randomized to the control arm will continue to manage their patients with chronic kidney disease according to routine primary care standards.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Annual Nephrology Evaluation	Patients with high risk chronic kidney disease (eGFR 30 to 45; or eGFR 45 to 60 with concurrent diabetes or proteinuria) should receive a nephrology office evaluation within the prior 12 months	At 18 months
Appropriate ACE/ARB Use	Patients with chronic kidney disease (eGFR 30 to 60) with concurrent diabetes, proteinuria, or hypertension should receive a prescription for ACE/ARB within the prior 12 months	At 18 months
Annual lab monitoring for CKD	Patients with chronic kidney disease (eGFR 30 to 60) should have the following labs checked within the prior 12 months: eGFR/ creatinine; Lipid profile; Calcium; Vitamin D; Parathyroid hormone; Phosphorous; Hemoglobin; Urine microalbumin	At 18 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Outcomes According to Primary Care Use	We will assess all three primary study outcomes according to the number of patient visits with their primary care physician during the 18 month period (0 visits, 1-2 visits, ≥ 3 visits).	At 18 months
Outcomes According to Physician Attitudes	We will assess all three primary care study outcomes according to physician attitudes as expressed in the post-intervention clinician survey. The three attitudes of interest include: Attitudes towards electronic decision support tools; Attitudes towards patient self management support; Self-assessed preparedness for managing chronic kidney disease	At 18 months

Collaborators and Investigators

• Sponsor: Brigham and Women's Hospital
• Collaborators: Harvard Vanguard Medical Associates
• Investigators: Principal Investigator: Thomas D Sequist, MD, MPH, Harvard Vanguard Medical Associates

Publications and helpful links

Helpful Links

• Harvard Vanguard Medical Associates

Study record dates

Study Major Dates

• Study Start: May 1, 2011
• Primary Completion (Actual): January 1, 2013
• Study Completion (Actual): January 1, 2013

Study Registration Dates

• First Submitted: September 15, 2010
• First Submitted That Met QC Criteria: September 15, 2010
• First Posted (Estimate): September 16, 2010

Study Record Updates

• Last Update Posted (Estimate): February 15, 2013
• Last Update Submitted That Met QC Criteria: February 14, 2013
• Last Verified: February 1, 2013

More Information

Terms related to this study

• Keywords: Chronic kidney disease; Quality improvement; Clinical decision support; Electronic health records; Self management support; Electronic reminders; Patient outreach
• Additional Relevant MeSH Terms: Urologic Diseases; Renal Insufficiency; Kidney Diseases; Renal Insufficiency, Chronic
• Other Study ID Numbers: 5R18HS018226-02 (U.S. AHRQ Grant/Contract)